Adjuvant Chemotherapy
A 77-year-old woman in good health with an ER-negative, PR-negative, HER2-negative tumor and three positive nodes wishes to receive chemotherapy. What would you likely recommend?
What is the age of the oldest breast cancer patient you have treated with adjuvant chemotherapy?
A 60-year-old woman has well-controlled hypertension. What would you tell her is the risk of heart failure for four courses of AC (240 mg/m
2
)?
How would you compare docetaxel/
cyclophosphamide (TC) to AC?
How would you compare docetaxel/
cyclophosphamide (TC) to AC?
How would you compare docetaxel/
cyclophosphamide (TC) to AC?
All other factors being the same and with the same risk of relapse, I am less likely to use adjuvant chemotherapy for women with ER-positive tumors than for women with ER-negative tumors.
You estimate a 10 percent risk of recurrence for a 65-year-old woman with an
ER-negative
, HER2-negative tumor. How likely would you be to recommend chemotherapy for this patient?
You estimate a 10 percent residual risk of recurrence for a 65-year-old woman with an
ER-positive
, HER2-negative tumor
after receiving adjuvant hormonal therapy
. How likely would you be to recommend chemotherapy for this patient?
There is essentially no role for the Onco
type
DX
TM
assay in the management of HER2-positive tumors.
Assays like Onco
type
DX will eventually replace IHC and FISH for evaluating HER2 and ER.
The way I integrate Onco
type
DX into my practice is cost effective for the healthcare system.
How useful is the Onco
type
DX assay for a patient with a node-negative, ER-positive tumor which is:
How useful is the Onco
type
DX assay for a patient with a node-negative, ER-positive tumor which is:
How useful is the Onco
type
DX assay for a patient with a node-negative, ER-positive tumor which is:
With regard to the TAILORx trial, how comfortable are you with the major paths of the three study groups?
With regard to the TAILORx trial, how comfortable are you with the major paths of the three study groups?
With regard to the TAILORx trial, how comfortable are you with the major paths of the three study groups?
